CNTX-4975 clinical trials
Also written CNTX-4975.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses CNTX-4975 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CNTX-4975
- 4
Studies by the year they started
4 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2014 | 1 |
| 2015 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Centrexion Therapeutics (4)
Studies
Open first, then newest update. How each study uses CNTX-4975 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)CompletedPhase 2Centrexion TherapeuticsNCT02678793Written as CNTX-4975
- Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee PainCompletedPhase 2Centrexion TherapeuticsNCT02558439Written as CNTX-4975
- A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)CompletedPhase 2Centrexion TherapeuticsNCT02283957Written as CNTX-4975
- Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)CompletedPhase 2Centrexion TherapeuticsNCT00667654Written as CNTX-4975